Publications by authors named "D Campodonico"
Article Synopsis
- Tramadol is a minor opioid used for pain management, and this study examines how variations in eight candidate genes (including CYP2D6 and CYP2B6) affect its effectiveness and safety.
- Researchers recruited 108 post-surgery patients, genotyped them, and measured tramadol metabolite levels, finding that CYP2D6 metabolizer status significantly influenced drug concentration post-administration.
- The study also revealed that certain genetic profiles (like CYP2B6 poor metabolizers) related to better pain relief and fewer side effects, while other profiles (CYP3A4 intermediate and poor metabolizers) showed higher rates of drowsiness and dizziness, highlighting the need for further research on genetic impacts on tramadol response.
Background: Severe cases of lymphopenia have been reported during siponimod clinical trials, which may negatively impact its benefit/risk profile.
Objective: We aimed to evaluate the incidence of lymphopenia following the initiation of siponimod treatment in clinical practice. The secondary objectives included the analysis of factors predisposing to and the clinical relevance of lymphopenia events.
A cost analysis of thiopurine treatment was carried out in 257 patients, with 153 preemptively genotyped for and 104 retrospectively genotyped in a Spanish setting. The healthcare cost was significantly higher in patients retrospectively genotyped compared to those who were preemptively genotyped ( < 0.001).
View Article and Find Full Text PDFArticle Synopsis
- Rivaroxaban is a direct factor Xa inhibitor and part of a drug class known as direct oral anticoagulants (DOACs), which serve as alternatives to traditional blood thinners like warfarin.
- Despite their popularity, variability in how different individuals respond to DOACs can lead to ineffective treatment or adverse effects such as bleeding or blood clots.
- A study involving 60 healthy volunteers explored the influence of factors like food intake, sex, biogeographical background, and genetic variations on the metabolism of rivaroxaban, revealing that those with slow NAT2 acetylation had notable changes in drug levels, suggesting a need for further research on genetic impacts on rivaroxaban's effectiveness.
Article Synopsis
- Cinitapride is a gastrointestinal drug used for functional dyspepsia and gastroesophageal reflux disease, and this study investigates the effects of genetic variants on its pharmacokinetics and safety.
- Researchers genotyped healthy volunteers for variants in 19 pharmacogenes, identifying that carriers of the CYP2C8*3 allele had significantly reduced drug exposure, while *4 allele carriers had increased exposure, although not statistically significant.
- The study helps define pharmacogenetic phenotypes for metabolizers of cinitapride, emphasizing the need for further research to fully understand the implications for other drugs metabolized by CYP2C8.